EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug‐Resistant HIV‐1 in Southeastern France

Syrine Boujamline, Celine Boschi, Hugo Bes-Barlandier iD, Christelle Tomei, Amelie Menard, Saadia Mokhtari, Isabelle Ravaux, Yacine Belkhir, Nadege Neant, Caroline Solas iD, Philippe Colson iD, Matthieu Million iD

Journal of Medical Virology · 2026

DOI: 10.1002/jmv.71149 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Syrine Boujamline und 11 weiteren Autor:innen. Beteiligte Einrichtung: IHU Mediterranée Infection, Marseille, France. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Anti-HIV Agents, Organophosphates. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, Contrat Plan Etat-Region, FEDER IHUPERF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lenacapavir and fostemsavir, two recently approved anti‐HIV‐1 agents, are promising options for people with difficult‐to‐treat HIV; however, real‐world data remain limited. This study aimed to describe the epidemiological, clinical, and virological profiles of people receiving combination antiretroviral regimens, including lenacapavir and/or fostemsavir. This retrospective study included adults living with HIV‐1 treated by lenacapavir and/or fostemsavir in our center (Marseille, France), between January 2023 and June 2024, with follow‐up continuing until July 2025. Clinical and biological data, including genotypic drug resistance testing and therapeutic drug monitoring, were extracted from electronic health records. The study included 21 people with HIV‐1 (14 men; mean age, 56 years), representing 1.0% of our active HIV cohort in 2023 ( n = 2,126). Virological and immunological failure and treatment intensification were the main reasons for switching therapy. Before switching, viral load was detectable in 11 persons; 8 (73%) achieved undetectable viral load at 24 months, whereas 3 (27%) nonadherent people with lower CD4 nadirs, higher baseline viral loads, and lower baseline CD4 counts remained persistently viremic. All three developed high‐level genotypic resistance, including M426L and/or S375T for fostemsavir (two people) and Q67H, K70R, N74S, and/or A105AT for lenacapavir (two people). One developed resistance to both drugs. In one of these 3 persistently viremic PWH, a dual‐injectable rescue regimen combining lenacapavir and cabotegravir achieved viral suppression at 33 months with maintenance through the end of follow‐up, bringing the success rate to 9 out of 11 (82%) among PWH who were viremic at baseline. No severe lenacapavir‐ or fostemsavir‐related adverse events were observed. This small real‐world study supports the effectiveness and safety of lenacapavir and/or fostemsavir in people with multidrug‐resistant HIV and variable adherence. All adherent people achieved viral suppression, whereas drug‐resistant HIV‐1 emerged in three people with poor adherence. A dual‐injectable rescue regimen may represent a last‐resort option in selected complex cases. Similar real‐world studies should be expanded, and adherence support should be strengthened.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsAnti-HIV AgentsOrganophosphatesPiperazinesDrug Resistance, Multiple, ViralHumansFranceRetrospective StudiesFemaleMiddle AgedMaleViral LoadAdultGenotypeAgedDrug Therapy, CombinationAcetamidesIndazoles

Stichwörter der Autor:innen

HIV‐1antiretroviral therapyantiviral drug resistancefostemsavirlenacapavirreal‐world evidence

Substanzen

Anti-HIV AgentsfostemsavirOrganophosphatesPiperazineslenacapavirAcetamidesIndazoles

Autor:innen und Institutionen

  • IHU Mediterranée Infection, Marseille, France.
  • AP-HM, Hôpital de la Timone, Marseille, France.
  • Aix-Marseille Univ, Microbes Evolution PHylogeny and Infection (MEPHI), UR D-258, Marseille, France.
  • Laboratoire de Pharmacocinetique et de Toxicologie, Hôpital de la Timone, APHM, Marseille, France.
  • Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), France.

ORCID-Profile: Hugo Bes-Barlandier, Caroline Solas, Philippe Colson, Matthieu Million

Förderung

  • Agence Nationale de la Recherche
  • Contrat Plan Etat-Region
  • FEDER IHUPERF

Zitieren

APA

Boujamline, S., Boschi, C., Bes-Barlandier, H., Tomei, C., Menard, A., Mokhtari, S., Ravaux, I., Belkhir, Y., Neant, N., Solas, C., Colson, P., & Million, M. (2026). Real‐World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug‐Resistant HIV‐1 in Southeastern France. Journal of Medical Virology. https://doi.org/10.1002/jmv.71149

Vancouver

Boujamline S, Boschi C, Bes-Barlandier H, Tomei C, Menard A, Mokhtari S, et al. Real‐World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug‐Resistant HIV‐1 in Southeastern France. Journal of Medical Virology. 2026. doi:10.1002/jmv.71149

BibTeX
@article{Boujamline2026,
  author = {Boujamline, Syrine and Boschi, Celine and Bes-Barlandier, Hugo and Tomei, Christelle and Menard, Amelie and Mokhtari, Saadia and Ravaux, Isabelle and Belkhir, Yacine and Neant, Nadege and Solas, Caroline and Colson, Philippe and Million, Matthieu},
  title = {Real‐World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug‐Resistant HIV‐1 in Southeastern France},
  journal = {Journal of Medical Virology},
  year = {2026},
  doi = {10.1002/jmv.71149}
}
Kostenlos starten →